tirzepatide action mechanism of (MOA) of Shifting the Scales: Tirzepatide's Breakthrough

DTPA, Diethylene Triamine Pentaacetic Acid

Rather than developing another pure GLP-1 agonist, Lilly pursued a dual-mechanism approach targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors

The nausea some patients experience may discourage fluid intake, and reduced eating often means reduced drinking too

J., Cheng, A

RELATED: New GLP-1 drugs could suppress desire for more than just food, study suggests For patients with a body mass index (BMI) of over 35, the heaviest people in the trial, the weight loss was even higher: They lost an average of 85 pounds, or 30.3% of their body weight, after two years